SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-058218
Filing Date
2023-03-02
Accepted
2023-03-02 16:21:58
Documents
12
Period of Report
2023-03-02
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d459859d8k.htm   iXBRL 8-K 25271
  Complete submission text file 0001193125-23-058218.txt   147361

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA cdtx-20230302.xsd EX-101.SCH 2834
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE cdtx-20230302_lab.xml EX-101.LAB 17993
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cdtx-20230302_pre.xml EX-101.PRE 11250
6 EXTRACTED XBRL INSTANCE DOCUMENT d459859d8k_htm.xml XML 3357
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

IRS No.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36912 | Film No.: 23699283
SIC: 2836 Biological Products, (No Diagnostic Substances)